{
  "publication/title": "Machine learning based anti-cancer drug response prediction and search for predictor genes using cancer cell line gene expression",
  "publication/authors": "The authors who contributed to this article are Kexin Qiu, JoongHo Lee, HanByeol Kim, Seokhyun Yoon, and Keunsoo Kang.\n\nKexin Qiu was involved in conceptualization, formal analysis, methodology, and writing the original draft. JoongHo Lee contributed to the methodology. HanByeol Kim participated in formal analysis. Seokhyun Yoon was responsible for data curation, funding acquisition, and reviewing and editing the manuscript. Keunsoo Kang also contributed to data curation and reviewing and editing the manuscript.",
  "publication/journal": "Genomics & Informatics",
  "publication/year": "2021",
  "publication/pmid": "33840174",
  "publication/pmcid": "PMC8042299",
  "publication/doi": "https://doi.org/10.5808/gi.20076",
  "publication/tags": "- Cell line gene expression data\n- Drug response prediction\n- Machine learning\n- Predictor genes\n- Precision medicine\n- Cancer therapy\n- Targeted anti-cancer therapy\n- ElasticNet regression\n- Genomic specificity\n- Artificial intelligence",
  "dataset/provenance": "The dataset utilized in this study originates from the Genomics of Drug Sensitivity in Cancer (GDSC), developed by the Sanger Research Institute in the United Kingdom. This dataset encompasses gene expression data for 1,000 human cancer cell lines. The specific drug response indicators considered are the half maximal inhibitory concentration (IC50) and the area under the curve (AUC). IC50 represents the concentration at which a compound achieves a 50% reduction in cell viability, while AUC is the area under the fitted dose-response curve. Biologically, lower values of IC50 and AUC indicate a greater response of cancer cells to the drug. The dataset includes information on 12 different drugs, providing a comprehensive basis for analyzing drug responses across various cancer cell lines. This dataset has been previously used in the community for similar studies, establishing its relevance and reliability in the field of cancer genomics and drug response prediction.",
  "dataset/splits": "Not enough information is available.",
  "dataset/redundancy": "Not enough information is available.",
  "dataset/availability": "The data used in this study is from the Genomics of Drug Sensitivity in Cancer (GDSC) dataset. This dataset is publicly available and provides a comprehensive resource for therapeutic biomarker discovery in cancer cells. The dataset includes drug response data, such as IC50 and AUC, as well as gene expression data for various cell lines. The specific data splits used in our experiments are not explicitly detailed in the public release, as the focus was on the methodology and results of the drug response predictions.\n\nThe GDSC dataset is accessible through its official website, and users can download the data for research purposes. The licensing details for the dataset can be found on the GDSC website, which typically allows for academic and non-commercial use with proper citation. To ensure compliance, users are required to adhere to the terms and conditions specified by the dataset providers. This includes acknowledging the source of the data in any publications or presentations resulting from its use.\n\nThe dataset includes a binary indicator of drug response, labeling cell lines as either \"sensitive (S)\" or \"resistant (R)\" to specific drugs. This information is crucial for validating the predictive models and understanding the biological implications of the predictor genes. The dataset's public availability and the detailed documentation provided by the GDSC team facilitate reproducibility and further research in the field of precision medicine.",
  "optimization/algorithm": "The machine-learning algorithm class used in our study is regularized linear regression, specifically ElasticNet. ElasticNet is not a new algorithm; it was introduced to combine the properties of both Ridge (L2) and LASSO (L1) regression, providing a balance between the two. It is particularly useful when dealing with datasets that have a large number of correlated features, which is common in genomic data.\n\nThe reason ElasticNet was not published in a machine-learning journal is that it has been well-established in the literature since its introduction. Our work focuses on applying this existing algorithm to a specific problem in cancer genomics, rather than developing a new machine-learning algorithm. We chose ElasticNet because it effectively handles multicollinearity and performs both variable selection and regularization, making it suitable for predicting drug responses based on gene expression data.\n\nIn our experiments, we optimized the hyperparameters of ElasticNet, specifically the penalty weight \u03b1 and the relative weight of the L1 penalty \u03bb, to achieve the best predictive performance. This involved performing a grid search to find the optimal combination of these parameters for each drug. The results demonstrated that ElasticNet could accurately predict drug responses, with correlation coefficients exceeding 0.6 for all 12 drugs tested.",
  "optimization/meta": "The model described in this publication does not use data from other machine-learning algorithms as input. Instead, it relies on cancer cell line gene expression data and drug response data, specifically focusing on two indicators: IC50 and AUC. The primary method used for drug response prediction is the ElasticNet regression model, which combines both L1 and L2 penalties for feature selection and regularization.\n\nThe ElasticNet model is employed to predict drug responses based on the gene expression data. The process involves pre-selecting genes using the Pearson correlation coefficient and then applying ElasticNet regression for fine gene selection. This approach is used separately for IC50 and AUC to identify predictor genes for each drug.\n\nFor the optimization of hyperparameters, a grid search is performed to find the best combination of the penalty weight \u03b1 and the relative weight of the L1 penalty \u03bb. This ensures that the model achieves the best predictive performance for the drug responses.\n\nThe model does not constitute a meta-predictor, as it does not aggregate the predictions of multiple machine-learning methods. Instead, it focuses on a single regression model, ElasticNet, to predict drug responses. The training data used in this model is independent and consists of gene expression data and drug response data from the Genomics of Drug Sensitivity in Cancer (GDSC) dataset.",
  "optimization/encoding": "The data used in our study was sourced from the Genomics of Drug Sensitivity in Cancer (GDSC) dataset, which includes gene expression data for 1,000 human cancer cell lines and drug response data for 12 different drugs. The drug response indicators considered were the half maximal inhibitory concentration (IC50) and the area under the curve (AUC). IC50 represents the concentration at which a compound reduces cell viability by 50%, while AUC is the area under the fitted dose-response curve. Biologically, lower IC50 and AUC values indicate a greater response of cancer cells to the drug.\n\nBefore processing the data, we applied a logarithm transformation to the IC50 values to normalize the distribution. Additionally, we normalized the cell line gene expression data using the robust multichip average method. This preprocessing step helps to reduce variability and improve the reliability of the subsequent analyses.\n\nFor feature selection, we employed a two-step approach. First, we used the Pearson correlation coefficient to pre-select genes that showed a significant correlation with drug responses. Genes with a p-value of 0.05 or less were selected in this initial feature selection step. This method helps to filter out genes that are not strongly correlated with the drug responses, reducing the dimensionality of the data and focusing on the most relevant features.\n\nIn the second step, we applied ElasticNet regression, a linear regression model that incorporates both L1 and L2 regularization. ElasticNet is particularly useful when dealing with a large number of correlated features, as it helps to suppress overfitting and improve generalization. We performed ElasticNet regression separately on the two response indicators, IC50 and AUC, to identify common predictor genes. These common genes were then used to predict drug responses, aiming to achieve better or at least similar prediction performance compared to using genes selected separately for each response indicator. This approach ensures that the selected genes are robust and reliable predictors of drug responses.",
  "optimization/parameters": "In our study, we employed the ElasticNet model for drug response prediction, which involves two key hyperparameters: the penalty weight \u03b1 and the relative weight of \u21131 penalty \u03bb. The parameter \u03b1 is an arbitrary positive real number, while \u03bb ranges between 0 and 1. When \u03bb is set to 0, the model reduces to Ridge regression, which applies only \u21132 penalty. Conversely, when \u03bb is set to 1, the model becomes LASSO regression, applying only \u21131 penalty.\n\nTo determine the optimal values for these hyperparameters, we conducted a grid search across a set of combinations of \u03b1 and \u03bb. This process allowed us to identify the hyperparameter settings that yielded the best predictive performance for the drug response indicators, IC50 and AUC, across the 12 drugs studied. The grid search ensured that we systematically explored the hyperparameter space to find the configuration that minimized prediction error and maximized the correlation between predicted and measured drug responses.",
  "optimization/features": "The input features for our drug response prediction model are genes from the Genomics of Drug Sensitivity in Cancer (GDSC) dataset. The dataset includes gene expression data for 1,000 human cancer cell lines. Initially, the number of features (genes) is much larger than the number of samples, which can lead to overfitting. To address this, we performed feature selection in two steps.\n\nFirst, we pre-selected genes using the Pearson correlation coefficient between the drug response and the expression of each gene. Genes with a p-value of 0.05 or less were selected. This step was performed using the entire dataset to ensure that the selected genes were relevant to the drug response.\n\nNext, we applied ElasticNet, a linear regression model with both L1 and L2 regularization, to further select predictor genes among the pre-selected ones. ElasticNet is particularly useful when there are many correlated features, as it helps to appropriately select genes and suppress generalization error. This step was performed separately on the two response values, IC50 and AUC, to identify common predictor genes. These common genes were then used to predict drug response, aiming for better or at least similar prediction performance compared to separate predictions for the two response indicators. The feature selection process ensures that the final set of input features is optimized for predicting drug response.",
  "optimization/fitting": "In our study, the number of features, which are genes, is indeed much larger than the number of samples. This scenario can lead to overfitting, where the model performs well on training data but poorly on unseen data. To address this, we employed ElasticNet, a linear regression model that incorporates both L1 and L2 regularization. This dual regularization helps in selecting relevant features and suppressing generalization error, thereby mitigating overfitting.\n\nTo ensure that our model did not underfit, we performed a grid search to optimize the hyperparameters of ElasticNet. Specifically, we tuned the penalty weight \u03b1 and the relative weight of the L1 penalty \u03bb. This process allowed us to find the best combination of hyperparameters that achieved the highest predictive performance for drug response indicators, IC50 and AUC.\n\nAdditionally, we compared ElasticNet with other well-known models, Support Vector Regression (SVR) and XGBoost. SVR was configured with a radial basis function kernel to handle non-linear relationships, while XGBoost is an advanced gradient boosting algorithm. Our preliminary experiments indicated that ElasticNet had a lower tendency for overfitting compared to these models, as evidenced by the number of common predictor genes for the two response indicators being larger for ElasticNet.\n\nThe predictive performance of ElasticNet was further validated by achieving high Pearson correlation coefficients between the estimated and true values for both IC50 and AUC across 12 drugs. For instance, drugs like AZD6244, Nutlin-3a, and 17-AAG showed correlation coefficients exceeding 0.8, demonstrating the model's robustness and generalizability.",
  "optimization/regularization": "In our study, we employed ElasticNet as our primary regularization method to prevent overfitting. ElasticNet is a linear regression model that incorporates both L1 (lasso) and L2 (ridge) regularization. This dual regularization approach is particularly effective when dealing with a large number of correlated features, which is the case in our dataset where the number of genes (features) far exceeds the number of samples.\n\nThe use of L1 regularization helps in feature selection by driving some coefficients to zero, effectively performing variable selection. Meanwhile, L2 regularization helps in shrinking the coefficients, which reduces the complexity of the model and prevents overfitting. By combining these two types of regularization, ElasticNet balances between the benefits of both methods, leading to a more robust and generalizable model.\n\nWe chose ElasticNet over other models, such as Support Vector Regression (SVR) and XGBoost, based on preliminary experiments. These experiments showed that ElasticNet provided a better trade-off between bias and variance, resulting in lower overfitting compared to the other models. Additionally, ElasticNet's ability to handle multicollinearity among features made it a suitable choice for our dataset.\n\nTo further optimize the performance of ElasticNet, we conducted a grid search to fine-tune the hyperparameters, specifically the penalty weight \u03b1 and the relative weight of L1 penalty \u03bb. This process ensured that we achieved the best possible predictive performance for the drug response indicators, IC50 and AUC.",
  "optimization/config": "The hyper-parameter configurations and optimization parameters used in our study are detailed within the publication. Specifically, we discussed the use of ElasticNet, which involves two key hyper-parameters: the penalty weight \u03b1 and the relative weight of the \u21131 penalty \u03bb. The values for these hyper-parameters were optimized through a grid search process. The best-performing configurations for predicting drug response indicators, IC50 and AUC, are summarized in the results.\n\nThe optimization schedule involved performing grid searches to find the optimal combinations of \u03b1 and \u03bb for each of the 12 drugs studied. This process ensured that the model achieved the best possible predictive performance.\n\nRegarding the availability of model files and optimization parameters, the supplementary materials accompanying this article provide additional data and figures that support the findings. These materials can be accessed online, ensuring that the methods and results are reproducible. The article is distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.\n\nFor those interested in the specific details of the hyper-parameter configurations and optimization parameters, the supplementary figures and tables offer comprehensive insights. These resources are essential for replicating the experiments and validating the results presented in the study.",
  "model/interpretability": "The model employed in this study is not a blackbox model. The ElasticNet regression model used for drug response prediction is inherently interpretable due to its linear nature and the use of regularization techniques. This model provides a clear and concise way to understand the relationship between the predictor genes and the drug response indicators, IC50 and AUC.\n\nOne of the key features of ElasticNet is its ability to perform both L1 (LASSO) and L2 (Ridge) regularization, which helps in selecting a subset of relevant features (genes) while shrinking the coefficients of less important features. This feature selection process makes the model more interpretable by highlighting the most significant genes that contribute to the prediction of drug responses.\n\nIn our experiments, we optimized the hyperparameters of ElasticNet, specifically the penalty weight \u03b1 and the relative weight of the L1 penalty \u03bb, to achieve the best predictive performance. By doing so, we were able to identify a set of predictor genes for each drug that showed a strong correlation with the drug response indicators. For instance, drugs like AZD6244, Nutlin-3a, and 17-AAG demonstrated high correlation coefficients, indicating that the selected genes are reliable predictors of drug responses.\n\nFurthermore, we explored the use of common predictor genes for both IC50 and AUC to enhance the stability and reliability of the predictions. By fixing the relative weights of the L1 and L2 penalties and adjusting \u03b1, we obtained a set of common predictor genes that performed well for both response indicators. This approach not only improved the predictive performance but also provided a more biologically meaningful set of genes that are likely involved in the underlying mechanisms of drug response.\n\nThe heatmaps generated for the predictor genes of selected drugs, such as lapatinib, nilotinib, PD-0332991, and sorafenib, visually represent the expression levels of these genes in sensitive and resistant cell types. These heatmaps offer a clear example of how the model identifies and utilizes specific genes to differentiate between drug-sensitive and drug-resistant responses.\n\nIn summary, the ElasticNet model used in this study is transparent and interpretable, providing valuable insights into the genetic factors that influence drug responses. The use of regularization techniques and the identification of common predictor genes enhance the model's interpretability and its potential for practical applications in personalized medicine.",
  "model/output": "The model employed is a regression model, specifically ElasticNet, which is a type of linear regression that incorporates both L1 and L2 regularization. This approach is used to predict drug response indicators, namely IC50 and AUC. The ElasticNet model was chosen for its ability to handle a large number of correlated features, which is crucial given that the number of genes (features) significantly exceeds the number of samples. The model's performance was optimized through a grid search for the hyperparameters \u03b1 and \u03bb, ensuring the best predictive accuracy for the drug responses. The results indicate that the model achieves high correlation coefficients between the predicted and measured drug responses, with several drugs showing coefficients above 0.8. This suggests that the model is effective in predicting drug responses using gene expression data. Additionally, the use of common predictor genes across different response indicators further enhances the reliability and stability of the predictions.",
  "model/duration": "Not enough information is available.",
  "model/availability": "Not enough information is available.",
  "evaluation/method": "The evaluation of the method involved predicting two drug response indicators, IC50 and AUC, separately. For this, ElasticNet regression was employed, which includes two key hyperparameters: the penalty weight \u03b1 and the relative weight of \u21131 penalty \u03bb. These hyperparameters were optimized through a grid search to achieve the best performance. The correlation coefficient between the estimated and true IC50 values was higher than 0.65 for all 12 drugs tested, with three drugs reaching correlations above 0.8. Similar performance was observed for AUC, where two drugs showed correlation coefficients exceeding 0.8. The statistical significance of these results was confirmed with p-values less than 0.01 for the correlation coefficient of each drug.\n\nAdditionally, the method was evaluated using common predictor genes for both response indicators. The relative weights of the \u21131 and \u21132 penalties in ElasticNet were fixed at 0.5, and \u03b1 was adjusted to ensure a similar number of selected genes for both indicators. The intersection of these genes was used to obtain common predictors for drug response prediction. The performance was assessed by increasing the number of common genes and observing the predictive accuracy. It was found that the performance saturated or slightly decreased after reaching a peak. The optimal number of predictor genes was determined to be 200, which yielded Pearson correlation coefficients for IC50 and AUC higher than 0.7 for six drugs. This indicates that using common predictor genes can provide similar predictive performance, suggesting these genes are reliable predictors for both response indicators and are closely related to the underlying biological mechanisms governing drug response.",
  "evaluation/measure": "In our study, we primarily focused on two key drug response indicators: IC50 and AUC. To evaluate the performance of our predictive models, we utilized the Pearson correlation coefficient (PCC) between the estimated and true values for these indicators. This metric is widely recognized and used in the literature for assessing the accuracy of predictive models in drug response studies.\n\nFor IC50, we achieved correlation coefficients higher than 0.65 for all 12 drugs tested, with three drugs\u2014AZD6244, Nutlin-3a, and 17-AAG\u2014exceeding 0.8. Similarly, for AUC, drugs like 17-AAG and nilotinib showed correlation coefficients above 0.8. These results indicate a strong predictive performance, further supported by statistically significant p-values (all less than 0.01) for the correlation coefficients of each drug.\n\nWe also compared our results with existing prediction methods reported in the literature. For instance, our method outperformed previous approaches for most drugs, as evidenced by higher PCC values for both IC50 and AUC. This comparison underscores the robustness and reliability of our predictive model.\n\nAdditionally, we explored the use of common predictor genes for both IC50 and AUC. By fixing the relative weights of the \u21131 and \u21132 penalties in ElasticNet and adjusting the penalty weight \u03b1, we identified a set of 200 common predictor genes that yielded PCC values higher than 0.7 for six drugs. This approach not only simplified the model but also demonstrated that these common genes are closely related to the underlying biological mechanisms governing drug response.\n\nIn summary, our performance metrics\u2014specifically the PCC for IC50 and AUC\u2014are representative and comparable to those reported in the literature. The high correlation coefficients and statistical significance of our results highlight the effectiveness of our predictive model in accurately estimating drug responses.",
  "evaluation/comparison": "In the evaluation of our methods, we conducted a thorough comparison with publicly available methods using benchmark datasets. Specifically, we compared our ElasticNet regression approach with Support Vector Regression (SVR) and XGBoost, which are well-established methods in the field of drug response prediction. This comparison was performed using the Genomics of Drug Sensitivity in Cancer (GDSC) dataset, a widely recognized benchmark in the community.\n\nThe performance of these methods was assessed using Pearson's correlation coefficients (PCC) between the predicted and measured drug response indicators, specifically IC50 and AUC. The results, as depicted in a figure, showed that our ElasticNet method achieved competitive or superior performance compared to SVR and XGBoost for various drugs. For instance, ElasticNet demonstrated high correlation coefficients for drugs like AZD6244, Nutlin-3a, and 17-AAG, indicating its effectiveness in predicting drug responses.\n\nAdditionally, we performed a comparison with simpler baselines to ensure that the complexity of our model was justified. The ElasticNet method incorporates both L1 and L2 penalties, which allow for feature selection and regularization, respectively. This dual penalty structure was optimized through grid search to achieve the best performance. The results indicated that the ElasticNet method outperformed simpler models that relied solely on L1 (LASSO) or L2 (Ridge) penalties, highlighting the importance of the combined approach in capturing the underlying biological mechanisms governing drug response.\n\nIn summary, our evaluation included a comprehensive comparison with publicly available methods and simpler baselines, demonstrating the robustness and effectiveness of our ElasticNet-based approach in predicting drug responses.",
  "evaluation/confidence": "The evaluation of our method's performance includes several key aspects that demonstrate its statistical significance and superiority over other approaches. For the prediction of drug response indicators, IC50 and AUC, we achieved correlation coefficients higher than 0.65 for all 12 drugs tested, with some drugs reaching coefficients above 0.8. These results are statistically significant, as the p-value for the correlation coefficient of each drug was less than 0.01. This indicates a strong and reliable predictive performance.\n\nIn our experiments, we optimized the hyperparameters of the ElasticNet model through grid search, ensuring that the best possible performance was achieved. The use of common predictor genes for both IC50 and AUC further validated the robustness of our method. With only 200 predictor genes, we obtained Pearson correlation coefficients higher than 0.7 for both IC50 and AUC for six drugs, which is comparable to the performance using separate predictors for each response indicator. This suggests that the common predictor genes are more reliable and closely related to the underlying biological mechanisms governing drug response.\n\nAdditionally, we compared our results with existing prediction methods in the literature for the same GDSC dataset. Our method consistently performed better for most of the drugs tested, as evidenced by the higher Pearson correlation coefficients. This comparison underscores the superiority of our approach in accurately predicting drug responses.\n\nIn summary, the performance metrics presented in our study are statistically significant, and the results demonstrate that our method is superior to other existing methods. The use of common predictor genes and the optimization of hyperparameters further enhance the reliability and robustness of our predictions.",
  "evaluation/availability": "The raw evaluation files are not explicitly mentioned as being available for public release. The publication discusses the use of the Genomics of Drug Sensitivity in Cancer (GDSC) dataset for drug response prediction, but it does not provide details on the availability of the specific evaluation files used in the study. The supplementary materials are mentioned as being available online, but the specific contents of these materials are not detailed. Therefore, it is not clear whether the raw evaluation files are included in the supplementary materials or if they are available elsewhere. For more information on data availability, readers may need to refer to the supplementary materials or contact the authors directly."
}